These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 39076247)

  • 1. Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells.
    Al Agrafi F; Gaballa A; Hahn P; Arruda LCM; Jaramillo AC; Witsen M; Lehmann S; Önfelt B; Uhlin M; Stikvoort A
    Oncoimmunology; 2024; 13(1):2379063. PubMed ID: 39076247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
    Ganesan R; Chennupati V; Ramachandran B; Hansen MR; Singh S; Grewal IS
    Leukemia; 2021 Aug; 35(8):2274-2284. PubMed ID: 33526858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
    Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
    Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis.
    van Loo PF; Hangalapura BN; Thordardottir S; Gibbins JD; Veninga H; Hendriks LJA; Kramer A; Roovers RC; Leenders M; de Kruif J; Doornbos RP; Sirulnik A; Throsby M; Logtenberg T; Dolstra H; Bakker ABH
    Expert Opin Biol Ther; 2019 Jul; 19(7):721-733. PubMed ID: 31286786
    [No Abstract]   [Full Text] [Related]  

  • 5. A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells
    Arruda LCM; Stikvoort A; Lambert M; Jin L; Rivera LS; Alves RMP; De Moura TR; Mim C; Lehmann S; Axelsson-Robertson R; Dick JE; Mattsson J; Önfelt B; Carlsten M; Uhlin M
    Haematologica; 2022 Aug; 107(8):1786-1795. PubMed ID: 35142149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia.
    Bartels L; de Jong G; Gillissen MA; Yasuda E; Kattler V; Bru C; Fatmawati C; van Hal-van Veen SE; Cercel MG; Moiset G; Bakker AQ; van Helden PM; Villaudy J; Hazenberg MD; Spits H; Wagner K
    Cancer Res; 2019 Jul; 79(13):3372-3382. PubMed ID: 31064847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia.
    Zeng X; Zhang H; Guo J; Yang D; Zhu Y; Liu N; Tang J; Liu T; Zhao X
    Cell Mol Life Sci; 2024 Aug; 81(1):371. PubMed ID: 39196413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.
    Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D
    J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
    Snauwaert S; Vanhee S; Goetgeluk G; Verstichel G; Van Caeneghem Y; Velghe I; Philippé J; Berneman ZN; Plum J; Taghon T; Leclercq G; Thielemans K; Kerre T; Vandekerckhove B
    Haematologica; 2012 Oct; 97(10):1539-47. PubMed ID: 22532518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia.
    Perko R; Kang G; Sunkara A; Leung W; Thomas PG; Dallas MH
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):130-6. PubMed ID: 25445640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells.
    Bianchi M; Reichen C; Croset A; Fischer S; Eggenschwiler A; Grübler Y; Marpakwar R; Looser T; Spitzli P; Herzog C; Villemagne D; Schiegg D; Abduli L; Iss C; Neculcea A; Franchini M; Lekishvili T; Ragusa S; Zitt C; Kaufmann Y; Auge A; Hänggi M; Ali W; Frasconi TM; Wullschleger S; Schlegel I; Matzner M; Lüthi U; Schlereth B; Dawson KM; Kirkin V; Ochsenbein AF; Grimm S; Reschke N; Riether C; Steiner D; Leupin N; Goubier A
    Cancer Immunol Res; 2024 Jul; 12(7):921-943. PubMed ID: 38683145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
    Al-Hussaini M; Rettig MP; Ritchey JK; Karpova D; Uy GL; Eissenberg LG; Gao F; Eades WC; Bonvini E; Chichili GR; Moore PA; Johnson S; Collins L; DiPersio JF
    Blood; 2016 Jan; 127(1):122-31. PubMed ID: 26531164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.
    Herrmann AC; Im JS; Pareek S; Ruiz-Vasquez W; Lu S; Sergeeva A; Mehrens J; He H; Alatrash G; Sukhumalchandra P; St John L; Clise-Dwyer K; Zha D; Molldrem JJ
    Front Immunol; 2018; 9():3153. PubMed ID: 30713535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment.
    Nair-Gupta P; Rudnick SI; Luistro L; Smith M; McDaid R; Li Y; Pillarisetti K; Joseph J; Heidrich B; Packman K; Attar R; Gaudet F
    Blood Cancer J; 2020 Jun; 10(6):65. PubMed ID: 32483120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
    Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
    Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia.
    de Weerdt I; Lameris R; Ruben JM; de Boer R; Kloosterman J; King LA; Levin MD; Parren PWHI; de Gruijl TD; Kater AP; van der Vliet HJ
    Clin Cancer Res; 2021 Mar; 27(6):1744-1755. PubMed ID: 33451981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.
    Oberg HH; Janitschke L; Sulaj V; Weimer J; Gonnermann D; Hedemann N; Arnold N; Kabelitz D; Peipp M; Bauerschlag D; Wesch D
    J Leukoc Biol; 2020 Jun; 107(6):1081-1095. PubMed ID: 31833593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte Colony-Stimulating Factor Effectively Mobilizes TCR γδ and NK Cells Providing an Allograft Potentially Enhanced for the Graft-Versus-Leukemia Effect for Allogeneic Stem Cell Transplantation.
    Minculescu L; Sengelov H; Marquart HV; Ryder LP; Fischer-Nielsen A; Haastrup E
    Front Immunol; 2021; 12():625165. PubMed ID: 33777007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
    Bonifant CL; Szoor A; Torres D; Joseph N; Velasquez MP; Iwahori K; Gaikwad A; Nguyen P; Arber C; Song XT; Redell M; Gottschalk S
    Mol Ther; 2016 Sep; 24(9):1615-26. PubMed ID: 27401038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
    Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
    Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.